Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 217

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 217
---
800,000 common stock. Each option had an exercise price of $0.001 per common stock. |

Share-based
expenses recognized in the financial statements:

|                                     |     | Successor 
 2024      | For the period commencing July 24 through 
                               December 31 |     | Predecessor 
 2024        | For the period commencing January 1 through 
                                     July 23 |     | 2023 | For the year ended 
       December 31, |
|:------------------------------------|:----|:----------|------------------------------------------:|:----|:------------|--------------------------------------------:|:----|:-----|-------------------:|
| Research and development expenses   |     |           |                                       709 |     |             |                                         710 |     |      |                205 |
| General and administrative expenses |     |           |                                       580 |     |             |                                           - |     |      |                  - |
| Net loss and comprehensive loss     |     |           |                                     1,289 |     |             |                                         710 |     |      |                205 |

<div align='center'>F-28</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 8 – SHAREHOLDERS’ EQUITY (Cont.)

|                                              |     | Predecessor       |        |     |          |     |     |                                        |      |     |                           |   |
|                                              |     | Number of options |        |     | Weighted 
 average  
 exercise 
 price    |     |     | Weighted average remaining contractual 
 terms                                  
 (in years)                             |      |     | Aggregate intrinsic value |   |
| Outstanding at December 31, 2023             |     |                   |  5,657 |     |          | 100 |     |                                        | 9.88 |     |                           | - |
| Grants                                       |     |                   |  8,600 |     |          | 100 |     |                                        |   10 |     |                           | - |
| Outstanding at July 23, 2024                 |     |                   | 14,257 |     |          | 100 |     |                                        | 9.61 |     |                           | - |
| Vested and expected to vest at July 23, 2024 |     |                   |